Last reviewed · How we verify
NCT03727087
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma
trial testing Blood Sample Collection in Melanoma in 348 participants. Terminated before completion.
24 March 2020
Quick facts
| Lead sponsor | Exact Sciences Corporation |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 348 |
| Start date | 10 January 2019 |
| Primary completion | 24 March 2020 |
| Estimated completion | 24 March 2020 |
| Sites | 36 locations across United States |
Drugs / interventions tested
- Blood Sample Collection — full drug profile →
Conditions studied
- Melanoma — all drugs for Melanoma →
Sponsor
Exact Sciences Corporation
Who can join
18 and older, any sex, with Melanoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03727087
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood Sample Collection
Trials testing the same drug.
- NCT07436637 — Guardant Shield Colorectal Cancer Screening · NA · not yet recruiting
- NCT07054346 — Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 · Phase 1 · recruiting
- NCT06695494 — Enabling Genomic Testing in Cancer of Unknown Primary · recruiting
- NCT07405515 — Pathophysiology of Dysautonomia and Postural Tachycardia Syndrome (POTS) in Post-viral Syndromes and COVID-19 · NA · active not recruiting
- NCT05487248 — A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients · NA · active not recruiting
Other recruiting trials for Melanoma
Currently open trials in the same condition.
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
- NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting
Other Exact Sciences Corporation trials
Trials by the same sponsor.
- NCT05246839 — Informed Choice - Compass · terminated
- NCT05210283 — CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer · active not recruiting
- NCT04473625 — Stool Collection Sub-Study of Exact Sciences Protocol 2018-01 · completed
- NCT04395391 — Home Usability Study of the SARS-CoV-2 (COVID-19) Test · completed
- NCT04213326 — Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03727087 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Exact Sciences Corporation
- Last refreshed: 10 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03727087.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing